IGF-1 LR3 vs Myostatin Inhibitor
A side-by-side research comparison of IGF-1 LR3 and Myostatin Inhibitor across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | IGF-1 LR3 | Myostatin Inhibitor |
|---|---|---|
| Full name | Insulin-like Growth Factor-1 Long R3 | Myostatin Inhibitor Peptides (Anti-GDF-8) |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Research compound |
| Mechanism | Activates IGF-1R while evading IGFBP sequestration. Triggers PI3K/Akt/mTOR for protein synthesis, satellite cell proliferation, and amino acid uptake into muscle. | Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth. |
| Molecular weight | 9,111 Da | 2,000-15,000 Da (varies) |
| Half-life | 20-30 hours (vs 15 min native) | 4-48 hours (design-dependent) |
| Bioavailability | High (SubQ/IM) | Variable (SubQ) |
| Typical dose | 20-50 mcg | 50-500 mcg |
| Frequency | Daily (post-workout) | 3-7x per week |
| Route | Subcutaneous or intramuscular injection | Subcutaneous |
IGF-1 LR3 reported benefits
- Potent anabolic effects
- Hyperplasia (new muscle cells)
- Extended half-life
- Enhanced recovery
- Improved nutrient partitioning
- Satellite cell activation
Myostatin Inhibitor reported benefits
- Muscle growth promotion
- Strength increase
- Myostatin blockade
- Muscle wasting treatment potential
- Metabolic improvement
Related comparisons
Research and educational reference only. Not medical advice.